Scilex Holding (SCLXW) Revenue (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Revenue of $8.6 million in Q1 2026, up 77.69% quarter-over-quarter from $4.8 million in Q4 2025, and up 72.0% on a YoY basis from $5.0 million in Q1 2025.
Scilex Holding (SCLXW) Revenue (2022 - 2026) Analysis & Trends
Scilex Holding's Revenue history runs 5 years deep, the most recent figure standing at $8.6 million for Q1 2026.
- In Q1 2026, Revenue rose 72.0% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $33.9 million (down 33.15% YoY), while the FY2025 annual figure was $30.3 million, down 46.46% from the prior year.
- Revenue was $8.6 million for Q1 2026 at Scilex Holding, up from $4.8 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $16.4 million in Q2 2024 to a low of $4.8 million in Q4 2025.
- Historically, Revenue has averaged $10.6 million across 5 years, with a median of $10.6 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Revenue sank 67.52% in 2025, then jumped 72.0% in 2026.
- A 5-year view of Revenue shows it stood at $11.9 million in 2022, then gained by 12.95% to $13.5 million in 2023, then climbed by 10.68% to $14.9 million in 2024, then tumbled by 67.52% to $4.8 million in 2025, then jumped by 77.69% to $8.6 million in 2026.
- The last three Revenue figures came in at $8.6 million (Q1 2026), $4.8 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 10.29 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 19.80 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 24.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 15.00 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 16.29 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 8.62 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 6.96 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.34 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 11.49 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 8.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.60 Mn |
| Dec 31, 2025 | 4.84 Mn |
| Sep 30, 2025 | 10.56 Mn |
| Jun 30, 2025 | 9.90 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 14.90 Mn |
| Sep 30, 2024 | 14.44 Mn |
| Jun 30, 2024 | 16.37 Mn |
| Mar 31, 2024 | 10.88 Mn |
| Dec 31, 2023 | 13.46 Mn |
| Sep 30, 2023 | 10.12 Mn |
| Jun 30, 2023 | 12.58 Mn |
| Mar 31, 2023 | 10.58 Mn |
| Dec 31, 2022 | 11.92 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Jun 30, 2022 | 7.93 Mn |
| Mar 31, 2022 | 6.81 Mn |